Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials

British Journal of Cancer

Volumn 84, Issue 10, 2001, Pages 1424-1431

  Johnson, J I ^a   Decker, S ^a   Zaharevitz, D ^a   Rubinstein, L V ^b   Venditti, J M ^c   Schepartz, S ^c   Kalyandrug, S ^b   Christian, M ^b   Arbuck, S ^b   Hollingshead, M ^a   Sausville, E A ^a  

^a Developmental Therapeutics Program   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c SAIC FREDERICK INC   (United States)

Author keywords

Anticancer drug discovery; Clinical trials; In vitro to in vivo correlations

Indexed keywords

5,6 DIHYDROAZACITIDINE; AMONAFIDE; ANTINEOPLASTIC AGENT; BISANTRENE; BLEOMYCIN; CARACEMIDE; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DACTINOMYCIN; DIDEMNIN B; DOXORUBICIN; FAZARABINE; FLUDARABINE PHOSPHATE; FLUOROURACIL; HOMOHARRINGTONINE; MELPHALAN; MENOGARIL; MERBARONE; METHOTREXATE; MITOMYCIN C; PACLITAXEL; RHIZOXIN; SPIROMUSTINE; TIAZOFURIN; TRIMETREXATE; UNINDEXED DRUG; VINBLASTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; HISTOLOGY; HYDROGEN BOND; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; TUMOR MODEL; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; CLINICAL TRIALS, PHASE II; DISEASE MODELS, ANIMAL; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MICE; MODELS, BIOLOGICAL; NATIONAL INSTITUTES OF HEALTH (U.S.); TRANSPLANTATION, HETEROLOGOUS; UNITED STATES;

EID: 2042458747     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2001.1796     Document Type: Article

References (22)

1. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay
2. Development of human tumor xenograft models for in vivo evaluation of new antitumor drugs
3. Investigation of diverse systems for cancer chemotherapy screening
4. A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. I. A qualitative and quantitative characterization of known drug databases
5. Tumor development under angiogenic signaling: A dynamical theory of tumor growth, treatment response, and postvasular dormancy
6. The hollow fiber assay
7. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings
8. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines
9. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: Development of the mean graph and COMPARE algorithm
10. Prediction of biochemical mechanism of action from the in vitro antitumor screen of the National Cancer Institute
11. Angiogenesis in the hollow fiber tumor model influences drug delivery to tumor cells: Implications for anticancer drug screening programs
12. Human tumor xenograft models
13. Evolving approaches to cancer drug discovery and development at the National Cancer Institute, USA
14. Correlation of drug response in patients and in the clonogenic assay with solid human tumour xenografts
15. Preclinical drug development: Rationale and methods
16. Current NCI preclinical antitumor screening in vivo: Results of tumor panel screening, 1976-1982, and future directions
17. The chemotherapy program of the National Cancer Institute: History, analysis and plans